Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
Marinus Pharmaceuticals (Nasdaq: MRNS) will host an Investor and Analyst Day on September 20, 2024, from 9:00 a.m. to 12:00 p.m. Eastern Time in New York and via webcast. The event will focus on the company's development program for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC). Presentations will be given by Marinus management and key opinion leaders, with emphasis on the upcoming Phase 3 TrustTSC trial data readout expected in the first half of Q4 2024.
In-person attendance is to invited research analysts and institutional investors, while others can watch the live video webcast. Registration for the webcast is available on the company's Investor Relations website. A replay will be archived following the event.
Marinus Pharmaceuticals (Nasdaq: MRNS) ospiterà un Investor and Analyst Day il 20 settembre 2024, dalle 9:00 alle 12:00, orario della costa est degli Stati Uniti, a New York e via webcast. L'evento si concentrerà sul programma di sviluppo dell'azienda per la sospensione orale ZTALMY® (ganaxolone) per la complessità della sclerosi tuberosa (TSC). Le presentazioni saranno tenute dalla direzione di Marinus e da leader di opinione chiave, con un'enfasi sulla prossima lettura dei dati del trial di Fase 3 TrustTSC prevista per la prima metà del Q4 2024.
La partecipazione di persona è riservata agli analisti di ricerca e agli investitori istituzionali invitati, mentre altri possono seguire il webcast video in diretta. La registrazione per il webcast è disponibile sul sito web delle Relazioni con gli Investitori dell'azienda. Una registrazione sarà archiviata dopo l'evento.
Marinus Pharmaceuticals (Nasdaq: MRNS) llevará a cabo un Día de Inversores y Analistas el 20 de septiembre de 2024, de 9:00 a.m. a 12:00 p.m. hora del este en Nueva York y a través de un webcast. El evento se centrará en el programa de desarrollo de la empresa para la suspensión oral ZTALMY® (ganaxolone) en el complejo de esclerosis tuberosa (TSC). Las presentaciones serán realizadas por la dirección de Marinus y líderes de opinión clave, con énfasis en la próxima lectura de datos del ensayo de Fase 3 TrustTSC esperada en la primera mitad del cuarto trimestre de 2024.
La asistencia en persona está reservada para analistas de investigación e inversores institucionales invitados, mientras que otros pueden ver el webcast en vivo. La inscripción para el webcast está disponible en el sitio web de Relaciones con Inversores de la empresa. Se archivará una repetición después del evento.
Marinus Pharmaceuticals (Nasdaq: MRNS)는 2024년 9월 20일 오전 9시부터 오후 12시(동부 표준시)까지 뉴욕에서 투자자 및 애널리스트의 날을 개최하며, 웹캐스트를 통해 진행됩니다. 이번 행사는 ZTALMY® (가나졸론) 경구 현탁액의 결절성 경화증 복합체 (TSC)에 대한 회사의 개발 프로그램에 초점을 맞출 것입니다. 마리누스 경영진 및 주요 의견 리더들이 발표를 진행하며, 2024년 4분기 첫째 달에 예상되는 3상 TrustTSC 시험 데이터 리드아웃에 대한 강조가 있을 것입니다.
현장 참석은 초대된 연구 분석가 및 기관 투자자에게만 허용되며, 그 외의 사람들은 라이브 웹캐스트를 시청할 수 있습니다. 웹캐스트 등록은 회사의 투자자 관계 웹사이트에서 가능합니다. 이벤트 종료 후 재방송이 보관될 예정입니다.
Marinus Pharmaceuticals (Nasdaq: MRNS) organisera un Journée pour Investisseurs et Analystes le 20 septembre 2024, de 9h00 à 12h00, heure de l'Est à New York et en webcast. L'événement sera axé sur le programme de développement de l'entreprise pour la suspension orale ZTALMY® (ganaxolone) dans le cadre du complexe de sclérose tubéreuse (TSC). Des présentations seront faites par la direction de Marinus et des leaders d'opinion clés, en mettant l'accent sur la prochaine lecture des données de l'essai de Phase 3 TrustTSC prévue pour la première moitié du quatrième trimestre 2024.
La participation en personne est limitée aux analystes de recherche et investisseurs institutionnels invités, tandis que d'autres peuvent regarder le webcast vidéo en direct. L'inscription pour le webcast est disponible sur le site des Relations avec les Investisseurs de l'entreprise. Une rediffusion sera archivée après l'événement.
Marinus Pharmaceuticals (Nasdaq: MRNS) veranstaltet am 20. September 2024 von 9:00 bis 12:00 Uhr (Eastern Time) in New York und über einen Webcast einen Investor and Analyst Day. Die Veranstaltung wird sich auf das Entwicklungsprogramm des Unternehmens für die orale Suspension ZTALMY® (Ganaxolon) bei tuberöser Sklerose (TSC) konzentrieren. Präsentationen werden von der Geschäftsführung von Marinus und wichtigen Meinungsführern gehalten, mit besonderem Fokus auf die bevorstehende Datenauswertung der Phase 3 TrustTSC-Studie, die für die erste Hälfte des vierten Quartals 2024 erwartet wird.
Die persönliche Teilnahme ist für eingeladene Research-Analysten und institutionelle Investoren vorgesehen, während andere das Live-Video-Webcast verfolgen können. Die Registrierung für den Webcast ist auf der Investor Relations-Website des Unternehmens verfügbar. Eine Wiederholung wird nach der Veranstaltung archiviert.
- None.
- None.
The event will feature presentations from Marinus management and key opinion leaders with a focus on the Company’s development program for ZTALMY® (ganaxolone) oral suspension CV in tuberous sclerosis complex (TSC) ahead of the Phase 3 TrustTSC trial data readout anticipated in the first half of the fourth quarter of 2024.
In-person attendance is open to invited research analysts and institutional investors. All others are invited to watch the live video webcast. Live questions will be taken by in-person guests, and virtual participants may submit questions through the webcast platform.
To register for the video webcast, please visit the Investor Relations section of the Company's website at https://ir.marinuspharma.com/events-and-presentations/. A replay of the webcast will be archived on the Investor Relations section of the Company's website following the event.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819826403/en/
Investors
Sonya Weigle
Chief People and Investor Relations Officer
Marinus Pharmaceuticals, Inc.
sweigle@marinuspharma.com
Media
Molly Cameron
Director, Corporate Communications & Investor Relations
Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Source: Marinus Pharmaceuticals
FAQ
When is Marinus Pharmaceuticals (MRNS) hosting its Investor and Analyst Day?
What is the main focus of Marinus Pharmaceuticals' (MRNS) Investor Day event?
When is the Phase 3 TrustTSC trial data readout for Marinus Pharmaceuticals (MRNS) expected?
How can investors attend Marinus Pharmaceuticals' (MRNS) Investor and Analyst Day?
